Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease

Brain

Volumn 137, Issue 10, 2014, Pages 2834-2846

  Collin, Ludovic ^a   Bohrmann, Bernd ^a   Göpfert, Ulrich ^b   Oroszlan Szovik, Krisztina ^a   Ozmen, Laurence ^a   Grüninger, Fiona ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Lipid rafts; Tau immunotherapy; Tau pS422 antibody

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIBODY; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; SARCOSINE; SARKOSYL; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; CELL MEMBRANE; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HIPPOCAMPAL CA1 REGION; HUMAN; IMAGE PROCESSING; IMMUNOLOGY; LIPID RAFTS; LYSOSOME; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; TAU IMMUNOTHERAPY; TAU/PS422 ANTIBODY; TRANSGENIC MOUSE; WESTERN BLOTTING;

LIPID RAFTS; TAU IMMUNOTHERAPY; TAU/PS422 ANTIBODY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CA1 REGION, HIPPOCAMPAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYSOSOMES; MEMBRANE MICRODOMAINS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; SARCOSINE; TAU PROTEINS;

EID: 84908377705     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu213     Document Type: Article

References (55)

1. Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 2014; 127: 667-83.
2. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-29.
3. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002; 103: 26-35.
4. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011; 118: 658-67.
5. Bussiere T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP, et al. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol 1999; 97: 221-30.
6. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neuroscience 2014; 34: 4260-72.
7. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011; 286: 34457-67.
8. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-13.
9. Collin L, Usiello A, Erbs E, Mathis C, Borrelli E. Motor training compensates for cerebellar dysfunctions caused by oligodendrocyte ablation. Proc Natl Acad Sci USA 2004; 101: 325-30.
10. Congdon EE, Duff KE. Is Tau aggregation toxic or protective? J Alzheimers Dis 2008; 14: 453-7.
11. Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcg receptor endocytosis and is a prerequisite for acute Tau protein clearance. J Biol Chem 2013; 288: 35452-65.
12. d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013; 8: e62402.
13. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of Tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-97.
14. Eidenmuller J, Fath T, Maas T, Pool M, Sontag E, Brandt R. Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J 2001; 357 (Pt 3): 759-67.
15. Ferrari A, Ehler E, Nitsch RM, Gotz J. Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. FEBS Lett 2000; 486: 121-5.
16. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 2003; 278: 40162-8.
17. Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013; 8: e62143.
18. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010; 11: 155-9.
19. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-25.
20. Götz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L Tau. J Biol Chem 2001; 276: 529-34.
21. Götz J, Probst A, Mistl C, Nitsch RM, Ehler E. Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development. Mech Dev 2000; 93: 83-93.
22. Grueninger F, Bohrmann B, Christensen K, Graf M, Roth D, Czech C. Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422. Mol Cell Biochem 2011; 357: 199-207.
23. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 2010; 37: 294-306.
24. Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 2013; 288: 33081-95.
25. Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of Tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem 2006; 97: 1005-14.
26. Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011; 286: 15317-31.
27. Hardy J. An 'anatomical cascade hypothesis' for Alzheimer's disease. Trends Neurosci 1992; 15: 200-1.
28. Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI. Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 2012; 136: 8-22.
29. Jones EM, Dubey M, Camp PJ, Vernon BC, Biernat J, Mandelkow E, et al. Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption. Biochemistry 2012; 51: 2539-50.
30. Kaushik S, Massey AC, Cuervo AM. Lysosome membrane lipid microdomains: novel regulators of chaperone-mediated autophagy. EMBO J 2006; 25: 3921-33.
31. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004; 24: 3801-9.
32. Kins S, Kurosinski P, Nitsch RM, Götz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 2003; 163: 833-43.
33. Kokubo H, Helms JB, Ohno-Iwashita Y, Shimada Y, Horikoshi Y, Yamaguchi H. Ultrastructural localization of flotillin-1 to cholesterolrich membrane microdomains, rafts, in rat brain tissue. Brain Res Mol Brain Res 2003; 965: 83-90.
34. Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front Psychiatry 2011; 2: 59.
35. Kumari R, Francesconi A. Identification of GPCR localization in detergent resistant membranes. Methods Mol Biol 2011; 746: 411-23.
36. Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neuro-fibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28: 228-37.
37. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol 2003; 32: 1091-105.
38. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Transsynaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.
39. Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000; 275: 15733-40.
40. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-81.
41. Ozmen L, Albientz A, Czech C, Jacobsen H. Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice. Neurodegener Dis 2009; 6: 29-36.
42. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 2011; 286: 23063-76.
43. Pennanen L, Götz J. Different Tau epitopes define Abeta42-mediated tau insolubility. Biochem Biophys Res Commun 2005; 337: 1097-101.
44. Pooler AM, Hanger DP. Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans 2010; 38: 1012-5.
45. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013; 14: 389-94.
46. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15: 157-68.
47. St Pierre CA, Leonard D, Corvera S, Kurt-Jones EA, Finberg RW. Antibodies to cell surface proteins redirect intracellular trafficking pathways. Exp Mol Pathol 2011; 91: 723-32.
48. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics 2011; 8: 263-77.
49. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012; 9: 397-405.
50. Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Am J Pathol 2011; 179: 2533-50.
51. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease betaamyloid production. Biochim Biophys Acta 2010; 1801: 860-7.
52. Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC. Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry 2012; 51: 888-98.
53. Wegmann S, Medalsy ID, Mandelkow E, Muller DJ. The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proc Natl Acad Sci USA 2013; 110: E313-21.
54. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80: 402-14.
55. Yang DS, Lee JH, Nixon RA. Monitoring autophagy in Alzheimer's disease and related neurodegenerative diseases. Methods Enzymol 2009; 453: 111-44.